Attovia Therapeutics (NASDAQ:ATTO – Get Free Report) issued its earnings results on Monday. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02), Zacks reports. Attovia Therapeutics’s quarterly revenue was down 100.0% compared to the same quarter last year. During the same period last year, the company posted ($3.44) EPS.
Attovia Therapeutics Price Performance
ATTO opened at $15.96 on Tuesday. Attovia Therapeutics has a 12 month low of $12.94 and a 12 month high of $28.00. The stock has a fifty day moving average of $18.06.
Analyst Upgrades and Downgrades
ATTO has been the topic of several research reports. Morgan Stanley initiated coverage on Attovia Therapeutics in a report on Monday, August 31st. They set an “overweight” rating and a $39.00 price objective on the stock. Weiss Ratings began coverage on shares of Attovia Therapeutics in a research report on Monday, November 2nd. They set a “sell (e-)” rating on the stock. Royal Bank Of Canada initiated coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They issued an “outperform” rating and a $45.00 price target for the company. Zacks Research raised shares of Attovia Therapeutics to a “hold” rating in a research report on Friday, September 4th. Finally, Wall Street Zen upgraded shares of Attovia Therapeutics to a “sell” rating in a research note on Saturday, September 19th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $42.20.
About Attovia Therapeutics
Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. The company is working to address conditions in which existing treatments may not provide adequate efficacy, durability, or convenience.
Attovia uses its proprietary antibody-engineering and drug-development capabilities to discover and advance biologic therapies designed to modulate disease-driving immune pathways.
See Also
- Five stocks we like better than Attovia Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Attovia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Attovia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
